Eutilex유틸렉스

Eutilex remains loss-making with heavy debt, a leadership change and an adverse audit opinion on its half-year review, while its shares are down about a third over the past year.

Eutilex is a Korean biotech developing cell and gene therapies, including CAR-T candidates for solid tumours, plus a small IT services business. Trailing twelve-month revenue is about ₩7.7B against an operating loss of about ₩13.6B, and borrowings of about ₩14.7B far exceed reported cash of about ₩0.27B. Recent filings show a CEO change and an adverse audit opinion on the half-year review.

What stands out

• Trailing revenue is about ₩7.7B, while operating income is about -₩13.6B, an operating margin of about -176%.
• Liabilities are about 202% of equity, and borrowings of about ₩14.7B compare with cash of about ₩0.27B.
• Free cash flow over the trailing period is about -₩9.6B, so the company is burning cash.
• The shares closed at ₩959 on 2026-10-26, near the lower part of a 52-week range of ₩650 to ₩1,587, and are down 33.7% over one year.
• Filings in August 2026 include an adverse opinion on the half-year review and a warning-related notice about investment caution, and in late August and September a CEO change.

What to watch

• Whether the company resolves the adverse audit opinion and the capital impairment and equity concerns flagged in August filings.
• Progress of the CEO transition and any further filings about leadership or governance.
• Funding plans to cover the gap between borrowings and cash, and any update on the EU307 and EU103 pipeline; the data provided does not include upcoming result dates or clinical timelines.